Innovation
Advancing safer therapies for pain
By mapping and modeling human metabolic pathways, we engineered novel molecules that circumvents the hepatic and renal liabilities associated with current non-opioid analgesics.
Science
Technology that drives innovation in pain medicine
Our lead candidates are being developed for multiple pain indications including acute, post-operative, neuropathic, and in-hospital pain, with a focus on safety and efficacy.
Problem
Pain medicine today
Pain management is one of the most prevalent and costly public health issues worldwide. In the U.S., pain affects more adults than diabetes and cancer combined, and costs the healthcare system an estimated $635 billion annually. Current medications are either highly addictive or cause harm to the liver and kidney. There is a great unmet need for new, safe, and effective non-opioid pain medications.
Solution
SRP-001 and the library of compounds
SRPs have a unique profile as demonstrated in preclinical models:
Demonstrate signs of pain and fever reduction
Indicate a significantly lower potential for abuse due to its non-opioid profile
Show no liver toxicity, even with high dose treatment (unlike acetaminophen)
Show no high dose kidney toxicity (unlike NSAIDs)
Opportunity
Meeting the unmet needs
Pain affects more Americans than cancer, diabetes, and heart disease combined. Despite market size, current options remain limited by safety and addiction concerns. SRP-001 offers a differentiated, non-narcotic path forward.
In the United States alone, the pain management therapeutics market is projected to reach over >$80 billion by 2030.
Differentiation
Our difference
South Rampart Pharma, Inc.’s work to manage this complexity and avoid the limitations of existing pain relief therapies is grounded in three key areas:
Deep Expertise
Our highly experienced teamincludes industry veterans with a proven track record in building companies and leading NIH funded researchers with diverse expertise in neuroscience and pharmacological.
Pathway Characterization
Our in-depth molecular work has allowed us to characterize a range of crucial pathways associated with pain relief and analgesic drug metabolism.
Superior Physiological Modeling
Safety, Tolerability & Robust Pharmacokinetics demonstrated in the Completed Phase 1 RCT for SRP-001 with an unique mechanism of action.
Let's get in touch
